BR112021020253A2 - Método para tratar tumores - Google Patents

Método para tratar tumores

Info

Publication number
BR112021020253A2
BR112021020253A2 BR112021020253A BR112021020253A BR112021020253A2 BR 112021020253 A2 BR112021020253 A2 BR 112021020253A2 BR 112021020253 A BR112021020253 A BR 112021020253A BR 112021020253 A BR112021020253 A BR 112021020253A BR 112021020253 A2 BR112021020253 A2 BR 112021020253A2
Authority
BR
Brazil
Prior art keywords
treating tumors
tumors
effect
treating
epoxytiglienone
Prior art date
Application number
BR112021020253A
Other languages
English (en)
Portuguese (pt)
Inventor
Mathew Boyle Glen
Kingsley CULLEN Jason
Warren Reddell Paul
Gordon Parsons Peter
Anne Gordon Victoria
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of BR112021020253A2 publication Critical patent/BR112021020253A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021020253A 2019-04-12 2020-04-09 Método para tratar tumores BR112021020253A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (1)

Publication Number Publication Date
BR112021020253A2 true BR112021020253A2 (pt) 2021-12-07

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020253A BR112021020253A2 (pt) 2019-04-12 2020-04-09 Método para tratar tumores

Country Status (26)

Country Link
US (1) US12226391B2 (https=)
EP (1) EP3952858B1 (https=)
JP (2) JP2022528915A (https=)
KR (1) KR20210152531A (https=)
CN (1) CN113924091A (https=)
AU (1) AU2020256847B2 (https=)
BR (1) BR112021020253A2 (https=)
CA (1) CA3136216C (https=)
DK (1) DK3952858T3 (https=)
EA (1) EA202192757A1 (https=)
ES (1) ES3063750T3 (https=)
FI (1) FI3952858T3 (https=)
HR (1) HRP20260232T1 (https=)
IL (1) IL287210B2 (https=)
LT (1) LT3952858T (https=)
MX (1) MX2021012449A (https=)
MY (1) MY208979A (https=)
PL (1) PL3952858T3 (https=)
PT (1) PT3952858T (https=)
RS (1) RS67777B1 (https=)
SG (1) SG11202110599RA (https=)
SI (1) SI3952858T1 (https=)
SM (1) SMT202600066T1 (https=)
UA (1) UA129840C2 (https=)
WO (1) WO2020206504A1 (https=)
ZA (1) ZA202108677B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
IL289072B2 (en) 2019-06-19 2025-06-01 QBiotics Pty Ltd Biofilm disruption
JP2024546296A (ja) * 2021-12-21 2024-12-19 キューバイオティクス プロプライアタリー リミティド 結晶性中間体
CN120569368A (zh) * 2022-12-21 2025-08-29 Q生物股份有限公司 晶型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
UA118670C2 (uk) * 2013-04-18 2019-02-25 К'Юбайотікс Лімітед Способи та композиції для загоєння ран
JP2019523303A (ja) * 2016-07-28 2019-08-22 キューバイオティクス リミティド 治療方法
CN110461324A (zh) 2017-03-23 2019-11-15 Q生物股份有限公司 用于治疗或预防肿瘤的联合疗法

Also Published As

Publication number Publication date
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
IL287210B2 (en) 2025-07-01
AU2020256847A1 (en) 2021-11-11
PT3952858T (pt) 2026-02-26
IL287210B1 (en) 2025-03-01
SG11202110599RA (en) 2021-10-28
CA3136216A1 (en) 2020-10-15
CN113924091A (zh) 2022-01-11
EP3952858A1 (en) 2022-02-16
EP3952858B1 (en) 2025-12-17
ES3063750T3 (en) 2026-04-20
WO2020206504A1 (en) 2020-10-15
SMT202600066T1 (it) 2026-03-09
JP2022528915A (ja) 2022-06-16
ZA202108677B (en) 2026-03-25
AU2020256847B2 (en) 2025-05-15
IL287210A (en) 2021-12-01
US12226391B2 (en) 2025-02-18
DK3952858T3 (da) 2026-02-23
RS67777B1 (sr) 2026-03-31
JP2025060945A (ja) 2025-04-10
MY208979A (en) 2025-06-14
HRP20260232T1 (hr) 2026-03-27
PL3952858T3 (pl) 2026-03-30
EA202192757A1 (ru) 2022-02-11
FI3952858T3 (fi) 2026-02-18
MX2021012449A (es) 2021-11-12
CA3136216C (en) 2024-01-16
EP3952858A4 (en) 2022-05-25
KR20210152531A (ko) 2021-12-15
UA129840C2 (uk) 2025-08-20
SI3952858T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
BR112021020253A2 (pt) Método para tratar tumores
CY1125977T1 (el) Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης
UY38476A (es) Inhibidores de arg1 y/o arg2
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
PH12020550901A1 (en) Macrocyclic compounds for treating disease
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2018003198A (es) Moduladores de proteínas básicas de la hepatitis b.
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
BR112019005305A2 (pt) compostos espirocíclicos
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
HK1249469A1 (zh) 用RORγ抑制剂治疗癌症的方法
PH12017501879A1 (en) Methods for treating cancer
PH12018501451A1 (en) Formulations for treating bladder cancer
BR112017021194A2 (pt) compostos espirocíclicos
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX381092B (es) Inhibidores de fucosidasa.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112017022296A2 (pt) métodos para tratar câncer
WO2019241644A8 (en) Novel small molecule anticancer agents, combinations and uses thereof
WO2020067910A3 (en) Pharmaceutical formulation containing a selenitetriglyceride and a cytostatic for use in treatment of tumour

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]